OKT3 monoclonal antibody in pediatric kidney transplant recipients with recurrent and resistant allograft rejection

M. R. Leone, S. R. Alexander, J. M. Barry, K. Henell, M. B. Funnell, G. Goldstein, D. J. Norman

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Twelve pediatric patients, aged 28 months to 17 years, received OKT3 to reverse renal allograft rejection. In 11 patients, the rejection crisis was resistant to conventional antirejection therapy with high doses of prednisone or polyclonal antithymocyte globulin. Reversal of rejection was successful in 10 patients who completed a treatment course. Because of recurring resistant rejection, five patients received a second course of OKT3, which was successful in reversing the rejection crisis in two. Among these patients, the persistence or the appearance of high levels of circulating T3 lymphocytes after initiating the second treatment course correlated with treatment failure. The immediate side effects associated with OKT3 therapy were translent and medically manageable. We conclude that this monoclonal antibody preparation is a safe and effective treatment for pediatric renal allograft in recipients experiencing rejection crisis resistant to conventional therapy. However, the potential impact of this immunosuppressive medication on long-term renal allograft survival in this patient population remains to be determined.

Original languageEnglish (US)
Pages (from-to)45-50
Number of pages6
JournalThe Journal of pediatrics
Volume111
Issue number1
DOIs
StatePublished - Jul 1987

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'OKT3 monoclonal antibody in pediatric kidney transplant recipients with recurrent and resistant allograft rejection'. Together they form a unique fingerprint.

  • Cite this